Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.
Vericel Corporation (NASDAQ: VCEL) is a commercial-stage biopharmaceutical company focused on advanced therapies for the sports medicine and severe burn care markets. Its news flow centers on financial performance, adoption of its cell therapy and biologic products, and progress in clinical and manufacturing initiatives.
Investors following VCEL news can expect regular quarterly earnings releases detailing total revenue, product-level revenue for MACI and Burn Care (Epicel and NexoBrid), gross margin, net income or loss, adjusted EBITDA and operating cash flow. Vericel frequently provides financial guidance ranges for full-year revenue, MACI growth, gross margin and adjusted EBITDA margin, and may update these expectations as the year progresses.
Company updates also highlight operational metrics such as record MACI revenue, numbers of MACI implants and biopsies, growth in trained MACI Arthro surgeons, Epicel and NexoBrid biopsy and hospital order trends, and expansion of the MACI sales force. These disclosures offer insight into market penetration and utilization of Vericel’s therapies in orthopedic and burn care settings.
Vericel news items often include information on clinical and regulatory milestones, such as FDA IND clearance for the Phase 3 MACI Ankle clinical study and the initiation of the MACI Ankle MASCOT clinical trial. The company also announces participation in major investor and healthcare conferences, including events hosted by J.P. Morgan, Stephens, Wells Fargo and Truist Securities, where management discusses business performance and strategy.
This VCEL news page aggregates these press releases and related announcements so readers can review historical and recent developments around Vericel’s financial results, product adoption, clinical programs and corporate presentations in one place.
Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, along with CFO Joe Mara, will engage in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021, at 3:00 PM ET. A live webcast of the event will be accessible through the Investor Relations section of Vericel's website. The company leads in advanced therapies for sports medicine and severe burn care, marketing products like MACI® and Epicel®.
Vericel Corporation (NASDAQ:VCEL) announced the termination of its shareholder rights agreement, or "poison pill," which was set to expire on August 15, 2021. This action accelerates the expiration to February 11, 2021, with no required action from shareholders. CEO Nick Colangelo emphasized that this termination aligns with the company's goal of enhancing governance policies for shareholders.
Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing products such as MACI® and Epicel® for cartilage repair and skin replacement, respectively.
Vericel Corporation (NASDAQ:VCEL) announced a conference call for its fourth-quarter 2020 financial results on February 24, 2021, at 8:30 AM EST. The call will be available live via the Investors section of Vericel's website. The company specializes in advanced therapies for sports medicine and severe burn care, marketing cell therapy products MACI® and Epicel®. Additionally, it has exclusive rights for NexoBrid®, targeted toward severe thermal burns. For more information, visit Vericel's website.
Vericel Corporation (NASDAQ:VCEL) has appointed Joe Mara as its new Chief Financial Officer, effective immediately. With over 20 years of experience, including significant roles in the biotech sector at Biogen, Mara is expected to enhance Vericel's financial strategies. His background includes leadership in global financial planning and operations. Nick Colangelo, CEO, expressed confidence that Mara's expertise will support the company's growth in advanced therapies for sports medicine and severe burn care. Mara highlighted his excitement about Vericel's innovative product potential and growth opportunities.
Vericel Corporation (NASDAQ: VCEL) announced its preliminary financial results for the fourth quarter and full year ended December 31, 2020, highlighting a record total revenue range of $44.9-$45.4 million for Q4, a 15% increase year-over-year. Total product revenues for 2020 reached $123.9-$124.4 million, driven by strong sales of MACI and Epicel. Despite a healthy performance, the company experienced scheduling delays and cancellations due to COVID-19, with an estimated $2 million in revenue potentially deferred to 2021. Cash increased to approximately $100 million with no debt.
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care, announces that Nick Colangelo, President and CEO, will present a company overview at the 23rd Annual Needham Growth Conference. The virtual presentation is scheduled for January 15, 2021, at 1:15 p.m. Eastern Time. A live webcast will be available on the Investor Relations section of the Vericel website. Vericel specializes in cell therapy products such as MACI® and Epicel® for cartilage defects and severe burns, respectively.
Vericel Corporation (NASDAQ:VCEL) announced that UnitedHealthcare will expand its medical policy for MACI® to cover individuals with full-thickness cartilage defects in the patella and multiple knee defects. This policy change is set to take effect on February 1, 2021, providing coverage for over 26 million lives, making UnitedHealthcare the largest commercial payer in the U.S. CEO Nick Colangelo emphasized that this move aligns with MACI's label and will enhance patient access and support growth for the therapy in the future.
Vericel Corporation (NASDAQ:VCEL) announced that Nick Colangelo, President and CEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 11:40 a.m. Eastern Time. This virtual conference will showcase an overview of the company, renowned for its advanced therapies in sports medicine and severe burn care. A live webcast of the presentation can be accessed on the Investor Relations section of Vericel's website.
Vericel Corporation (NASDAQ:VCEL) announced its third quarter results for 2020, reporting total net revenues of $32.3 million, an increase from $30.5 million in Q3 2019. MACI® generated $24.4 million, while Epicel® and NexoBrid® brought in $6.7 million and $1.2 million, respectively. The company achieved a gross margin of 70% and net income of $3.6 million or $0.08 per share. Operating cash flow stood at $4.6 million, and cash reserves reached $85.5 million. The FDA has accepted NexoBrid's Biologics License Application with a PDUFA goal date of June 29, 2021.
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care, announced its participation in upcoming investor conferences. The company will present at the Credit Suisse 29th Annual Healthcare Conference on November 9, 2020, at 2:45 PM EST, and at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 2:40 PM EST. A live webcast will be available on the company's Investor Relations website.
FAQ
What is the current stock price of Vericel (VCEL)?
What is the market cap of Vericel (VCEL)?
